IMR Press / EJGO / Volume 39 / Issue 5 / DOI: 10.12892/ejgo4274.2018
Open Access Review
ARID1A mutation in endometrial cancer: a review
Show Less
1 Department of Obstetrics and Gynecology, Shanghai General Hospital of Shanghai Jiaotong University, Shanghai, China
Eur. J. Gynaecol. Oncol. 2018 , 39(5), 705–709; https://doi.org/10.12892/ejgo4274.2018
Published: 10 October 2018
Abstract

Endometrial carcinoma is the most frequent gynecological malignancy and a leading cause of cancer death in women worldwide. ARID1A, a gene participated in chromatin remodeling, is an emerging tumor suppressor gene. Accumulating evidence has reported somatic inactivating mutations of ARID1A and loss of its expression in many types of human cancers, especially in endometrium-derived tumors. The high prevalence of somatic mutations in endometrial cancers indicates a pivotal role of ARID1A in their development. Understanding the roles of ARID1A in the pathogenesis of endometrial carcinoma is fundamental for future translational studies aimed at designing new diagnostic tests for early detection and identifying critical molecular targets for new therapeutic interventions.
Keywords
ARID1A
Mutation
Endometrial cancer
ARID1B
Share
Back to top